Clinical trials: Movement Abnormalities
IDIOPATHIC PARKINSON'S DISEASE
Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
The primary objective is to demonstrate that the Rotigotine transdermal patch is efficacious in Chinese subjects with early-stage idiopathic Parkinson's disease.
- Trial name
- NCT01646268
- Testing
- Rotigotine
- Where
- 24 sites in China
- Volunteers
- 249 people
- Sponsor
- UCB Pharma
Parkinson's Disease
Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine
This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's…
- Trial name
- NCT00593606
- Testing
- Rotigotine
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Parkinson Disease
First-in-Human Single and Multiple Dose of HL-400
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending…
- Trial name
- NCT06997484
- Testing
- HL-400
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Highlightll Pharmaceutical (USA) LLC
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with…
- Trial name
- CLIN-011 (NCT04739423)
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 41 people
- Sponsor
- CuraSen Therapeutics, Inc.
Idiopathic Parkinson's Disease
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons.
- Trial name
- MOTION (NCT00605683)
- Testing
- Safinamide (as add-on therapy)
- Where
- 125 sites in United States, Argentina and 18 more
- Volunteers
- 679 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson's Disease, Idiopathic
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: The study duration will be up to 7-8 months.
- Trial name
- NCT05357989
- Testing
- buntanetap/posiphen
- Where
- 69 sites in United States, Germany and 4 more
- Volunteers
- 523 people
- Sponsor
- Annovis Bio Inc.
Alzheimer's Disease, Huntington's Disease
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin
To estimate the absorption, safety, and tolerability of a dimebon transdermal solution relative to the dimebon immediate release oral formulation.
- Trial name
- NCT00990613
- Testing
- Dimebon IR, Dimebon Transdermal
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chorea, Huntington
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.
- Trial name
- NCT06312189
- Testing
- Valbenazine
- Where
- 3 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Neurocrine Biosciences
Early Parkinson's Disease
SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease
This study is to evaluate the safety and efficacy of sustained release (SR)-Exenatide (PT320, Q1W and Q2W) in the treatment of patients with early Parkinson's disease (PD).
- Trial name
- NCT04269642
- Testing
- PT320 2.0 mg, PT320 2.5 mg
- Where
- 5 sites in South Korea
- Volunteers
- 99 people
- Sponsor
- Peptron, Inc.
Parkinson's Disease
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias
The purpose of this study is to investigate the safety, tolerability and efficacy of E2007 in Parkinson's Disease patients who have "wearing off" motor fluctuations and "on" period dyskenisias.
- Trial name
- NCT01172379
- Testing
- E2007
- Where
- 33 sites in Czechia, France and 4 more
- Volunteers
- 2 people
- Sponsor
- Eisai Limited
Parkinson Disease
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
The general aim of this study is to obtain long-term safety and tolerability data on pramipexole ER, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have previously completed a pramipexole double-blind…
- Trial name
- NCT00601523
- Testing
- Pramipexole
- Where
- 119 sites in United States, Austria and 13 more
- Volunteers
- 511 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.
- Trial name
- NCT00505687
- Testing
- Rotigotine
- Where
- 26 sites in United States, Austria and 6 more
- Volunteers
- 186 people
- Sponsor
- UCB Pharma
Parkinson Disease
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are…
- Trial name
- NCT04542499
- Testing
- Tavapadon
- Where
- 146 sites in United States, Australia and 12 more
- Volunteers
- 507 people
- Sponsor
- AbbVie
Parkinson Disease, Idiopathic
Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa
Male and female patients aged ≥ 30 years with advanced stage idiopathic Parkinson's disease, not well controlled on existing levodopa will take part in a research study at approximately 82 sites in Europe, Israel, South Africa…
- Trial name
- NCT00244387
- Testing
- SPM 962
- Where
- Germany
- Volunteers
- 506 people
- Sponsor
- UCB Pharma
Parkinson's Disease (PD)
A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease
The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications.
- Trial name
- NCT07647614
- Testing
- 60 milligrams of ENERGI-F705 Tablets, 120 milligrams of ENERGI-F705 Tablets
- Where
- 2 sites in Taiwan
- Volunteers
- 105 people
- Sponsor
- Energenesis Biomedical Co., Ltd.
Parkinson's Disease
Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects
This is a randomized, double-blind, placebo-controlled, parallel-group single ascending dose (SAD) study. Up to 5 cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
- Trial name
- NCT04043338
- Testing
- XC130-A10H
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Xoc Pharmaceuticals
Parkinson Disease, Dyskinesias
Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
This phase IIb study is designed to determine the safe and efficacious dose or dose range of AFQ056 for the treatment of patients with moderate to severe Parkinson's disease with L-Dopa induced dyskinesias.
- Trial name
- NCT00986414
- Testing
- AFQ056
- Where
- 47 sites in Australia, Canada and 6 more
- Volunteers
- 260 people
- Sponsor
- Novartis
Mild Cognitive Impairment, Dementia
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
This retrospective study is a more extensive, confirmatory analysis of the cognitive and functional outcomes initially seen in 2 groups of MCI/dementia patients in Springfield, MA and compares specialized dementia care and a…
- Conditions
- Mild Cognitive Impairment, Dementia, Hypoxia, Hyperhomocysteinemia
- Trial name
- NCT02860338
- Volunteers
- 900 people
- Sponsor
- Clionsky Neuro Systems Inc.
Tourette Syndrome
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome
The purpose of this clinical study is to verify the long term effectiveness and safety of a bilateral deep brain stimulation (DBS) produced by Beijing PINS Medical Co., Ltd.
- Trial name
- NCT02253498
- Testing
- deep brain stimulation (DBS)
- Volunteers
- 20 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Huntington's Disease
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
The primary purpose of this study is to assess the effect of food upon the pharmacokinetics (PK) of SEN0014196 in subjects with Huntington disease (HD).
- Trial name
- NCT01485965
- Testing
- SEN0014196
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Siena Biotech S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.